To evaluate the efficacy and safety of ofatumumab in patients with refractory anti-NMDAR encephalitis unresponsive to first-line and second-line immunotherapy, particularly focusing on the context of persistent symptoms.
Key Findings:
All three patients showed significant improvement in psychiatric symptoms and cognitive function after treatment, with specific metrics indicating a percentage change.
CD20+ B cell levels rapidly declined to extremely low levels.
Only one patient experienced mild bone pain and a low-grade fever; no severe adverse events were reported.
Interpretation:
Ofatumumab provides a rapid, safe, and effective approach to alleviate symptoms in refractory anti-NMDAR encephalitis, with potential implications for clinical practice.
Limitations:
The study consists of a small sample size with only three cases.
Current real-world data on OFA treatment for anti-NMDAR encephalitis is limited.
There is a lack of long-term follow-up data to assess sustained efficacy.
Conclusion:
Ofatumumab may be a promising therapeutic option for patients unresponsive to conventional treatments, highlighting the need for further studies to validate these findings.
